A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension-Reference-Cited by-同舟云学术

A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension

Published:2017-12-13 Issue:3 Volume:27 Page:125-133
ISSN:0803-7051
Container-title:Blood Pressure
language:en
Short-container-title:Blood Pressure

Author:

Rakugi Hiromi¹,Shimizu Kohei²,Nishiyama Yuya²,Sano Yuhei²,Umeda Yuusuke²

Affiliation:

1. Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan;

2. Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan

Funder

Takeda Pharmaceutical Company Limited

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/08037051.2017.1412797

Reference18 articles.

1. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)

2. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study

3. Drug safety evaluation of amlodipine

4. Evaluation of the Efficacy and Tolerability of Fixed-Dose Combination Therapy of Azilsartan and Amlodipine Besylate in Japanese Patients With Grade I to II Essential Hypertension

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mathematical Modeling of Antihypertensive Therapy with Azilsartan Medoxomil on the Example of Clinical Data of a Real Patient;Mathematical Biology and Bioinformatics;2023-06-30

2. Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects;Clinical Pharmacology in Drug Development;2019-09-25

3. Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018;International Journal of Molecular Sciences;2019-09-12

4. Correction to: Rakugi et al., A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension;Blood Pressure;2018-01-22

5. Diuretics;Side Effects of Drugs Annual;2018